A Phase 2 interventional study of Probiotics and Metformin in PreDiabetes, Impaired Glucose Tolerance and Hyperglycemia, sponsored by University of Guadalajara. Active, not recruiting at 1 site in Mexico. Open to participants aged 31 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by University of Guadalajara · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing metformin in Prediabetic State — 2 open to participants now, 4 under way, none of them phase 3. Metformin · Prediabetic State.
Among the 33 studies testing metformin in Prediabetic State, this one is the 24th largest by planned enrollment, is one of 4 that started in 2019, is one of 4 in phase 2, and was the 25th registered.
919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.
Browse Prediabetic State studies →2 of the 33 studies testing metformin in Prediabetic State are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18–75
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.
This study: 31 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 7 · Phase 4 14
First in 1996; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 62 across 763 interventional studies indexed under Prediabetic State.
Median enrollment 46 across the 33 interventional studies. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 33 has an industry lead sponsor. The 10 most frequent:
University of Guadalajara is the lead sponsor of 95 studies on the registry; 18 are open to participants now.
University of Guadalajara has 6 studies filed under Prediabetic State — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing metformin in Prediabetic State, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pre diabetes (PD) is a term that refers to alterations in blood glucose levels, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or both, and increase in glycated hemoglobin (HbA1c), all this factors involving a higher risk to develop type 2 diabetes mellitus (T2DM).
The efficacy of pharmacotherapy in the prevention of diabetes in adults with pre diabetes has been demonstrated, the first line of pharmacology treatment is metformin, on the other hand, probiotics administration has been reported to be one of the most widely used approaches to modulate the gut microbiota and subsequently prevent or delay the incidence of T2DM.
Probiotics are live microorganisms which when administered in adequate amounts confer a health benefit on the host. Has been demonstrated the hypoglycemic effects of the probiotics in different clinical trials in type 2 diabetes mellitus and pre diabetes, but no yet compared with metformin, for this reason comparing it´s activity against metformin in pre diabetes would provide impact information on a new alternative treatment compared with the standard pharmacological treatment.
The aim of the study is evaluate the effect of administration of probiotic versus metformin on glycemic control, insulin secretion and insulin sensitivity in patients with pre diabetes.
A randomized, double-blind controlled clinical trial in 30 patients between 31 to 60 years of age with a diagnosis of prediabetes (IFG 100 a 125 mg/dL, IGT 140 a 199 mg/dL, HbA1c 5.7 a 6.4%) in accordance with the American Diabetes Association without treatment.
Patients with one or more of the following criteria will be excluded: History of liver, kidney or heart disease; systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, HbA1c ≥6.5%, triglycerides ≥ 400 mg/dL, total cholesterol ≥240 mg/dL; pregnancy or lactation; consumption of medications or supplements with effects on glucose levels.
They will be assigned randomly two groups of 15 patients; one of the groups will receive 750 mg of metformin twice at day (before breakfast and dinner) for 13 weeks.
The other group will receive 400 mg of probiotics 1 time at day (before breakfast) and placebo pill (before dinner) for 13 weeks.
They will be measured fasting blood glucose, postprandial glucose levels and glycosylated hemoglobin, and will be calculated area under curve of glucose an insulin, total insulin secretion (Insolinogenic index), first-phase of insulin secretion (Strumvoll index) and insulin sensitivity (Matsuda index).
This protocol It´s already approved by the local ethics committee and written informed consent it´s going to be obtained from all volunteers.
Statistical analysis will be presented through measures of central tendency and dispersion, average and deviation standard for quantitative variables; frequencies and percentage for qualitative variable. Will be used Wilcoxon range test for identification of differences between baseline and final evaluation of each intervention group, Mann-Whitney U Test and Wilcoxon Test for the within-groups differences. It will be considered satitistical significance p >0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 patients to receive homologated intervention capsule (probiotics lactobacillus acidophilus y bifidobacterium lactis 400 mg) 1 time at day before breakfast along 13 weeks and receive 1 homologated placebo capsule (calcinated magnesia 500 mg) 1 time at day before dinner along 13 weeks.
Dietary Supplement: Probiotics
15 patients to receive homologated intervention capsule (metformin 750 mg) twice at day before breakfast and dinner for 13 weeks.
Drug: Metformin
Probiotics capsules (lactobacillus acidophilus y bifidobacterium lactis) 400 mg 1 time at day before breakfast and one placebo capsule before dinner during 13 weeks. Homologated to the other intervention.
Metformin capsules, 750 mg, two pere day before breakfast and dinner during 13 weeks. Homologated to the other intervention.
Fasting glucose levels
The fasting glucose levels will be evaluated at baseline and week 13 by enzymatic- colorimetric technique to get fasting glucose level
Time frame: Baseline to week 13 (end of intervention)
Postpandrial glucose levels
Glucose will be evaluated at baseline and week 13 after a oral glucose tolerance test with enzymatic-colorimetric technique
Time frame: Baseline to week 13 (end of intervention)
Glycosylated hemoglobin
Glycosylated hemoglobin will be evaluated at baseline and week 13 by high efficiency liquid chromatography.
Time frame: Baseline to week 13 (end of intervention)
Insulin sensitivity
Insulin sensitivity will be calculated at baseline and week 13 with Matsuda index to get insuline sensitivity
Time frame: Baseline to week 13 (end of intervention)
Total insulin secretion
Total insulin secretion will be calculated at baseline and week 13 with Insulinogenic index to get total insulin secretion
Time frame: Baseline to week 13 (end of intervention)
First phase of insuline secretion
The first phase if insuline secretion will be calculated at baseline and week 13 with Stumvoll index to get first phase of insuline secretion
Time frame: Baseline to week 13 (end of intervention)
Body weight
Body weight will be measured at baseline and week 13 with a bioimpedance balance
Time frame: Baseline to week 13 (end of intervention)
Body mass index (BMI)
Body mass index will be calculated at baseline and week 13 with the Quetelet index formula
Time frame: Baseline to week 13 (end of intervention)
Waist circunference
Waist circunference will be evaluated at baseline and week 13 by World Health Organization technique
Time frame: Baseline to week 13 (end of intervention)
Blood pressure
Systolic blood pressure and diastolyc blood pressure will be measured at baseline and week 13 with a digital sphygmomanometer three times in each arm to get an average
Time frame: Baseline to week 13 (end of intervention)
Total cholesterol
Total chilesterol level will be evaluated at baseline and week 13 by enzymatic- colorimetric technique to get total cholesterol level
Time frame: Baseline to week 13 (end of intervention)
High density lipoprotein (c-HDL)
High density lipoprotein (c-HDL) level will be evaluated at baseline and week 13 by enzymatic- colorimetric technique to get c-HDL level
Time frame: Baseline to week 13 (end of intervention)
Low density lipoprotein (c-LDL)
Low density lipoprotein (c-LDL) level will be calculated at baseline and week 13 with Friedewald formula to get c-LDL level
Time frame: Baseline to week 13 (end of intervention)
Very low density lipoprotein (VLDL)
Very low density lipoprotein (VLDL) level will be calculated at baseline and week 13 with triglycerides concentration/5 formula to get VLDL level
Time frame: Baseline to week 13 (end of intervention)
Fasting blood triglycerides concentration
Fasting blood triglycerides concentration level will be evaluated at baseline and week 13 by enzymatic- colorimetric technique to get triglycerides concentration
Time frame: Baseline to week 13 (end of intervention)
Concentration of blood creatinine
Concentration of blood creatinine level will be evaluated at baseline and week 13 by enzymatic-colorimetric technique to get creatinine level
Time frame: Baseline to week 13 (end of intervention)
Concentration of blood alanine aminostranferase (ALT)
Concentration of blood alanine aminostranferase level will be evaluated at baseline and week 13 by enzymatic-colorimetric technique to get ALT level
Time frame: Baseline to week 13 (end of intervention)
Concentration of blood aspartate aminostranferase (AST)
Concentration of blood aspartate aminostranferase level will be evaluated at baseline and week 13 by enzymatic-colorimetric technique to get AST level
Time frame: Baseline to week 13 (end of intervention)
Incidence of treatment-Emergent Adverse Events
Incidence of treatment-Emergent Adverse Events of probiotics+placebo or metformin will be identified by clinical evaluation from baseline week to week 13 with continuous surveiilance
Time frame: Baseline to week 13 (continuous surveiilance)
Started Oct 2019 (actual). Primary completion is estimated for Dec 2027, 98 months after the start.
Of 27 phase 2 interventional studies under Prediabetic State, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 69. This study's planned 98 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Jun 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
University of Guadalajara